Keywords: EU Commission, Ant-trust, Kundbeck, Pay-for-delay settlements, Patents
EU Commission moves forward on anti-trust issues with Lundbeck and others
Article | 26 July 2012
The European Commission yesterday advised Danish CNS drug specialist Lundbeck (LUN: CO) of its objections regarding agreements concluded with four ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
